Regeneus lines up manufacturer for US CryoShot trial
22 January, 2014 by Dylan Bushell-EmblingGlobal stem cell manufacturer Lonza has agreed to produce the stocks of Regeneus' (ASX:RGS) cell therapy CryoShot Canine for an upcoming US marketing study.
Phosphagenics in for Indian royalties from TPM gels
21 January, 2014 by Dylan Bushell-EmblingPhosphagenics' (ASX:POH) Indian partner Themis and Novartis are both launching into the Indian market diclofenac gel products which use Phosphagenics' TPM drug-delivery technology.
Economic industry reviews for Vic and SA to inform manufacturing transition
21 January, 2014In a call for submissions, federal Industry Minister Ian Macfarlane has announced reviews for Victoria and South Australia to guide Australia's transition to "a new era of manufacturing and competitiveness" in preparation for the departure of Ford and Holden's manufacturing.
First UK NHS patient treated with Iluvien: pSivida
17 January, 2014 by Dylan Bushell-EmblingpSivida (ASX:PVA) licensee Alimera Sciences has announced that the first UK NHS patient has been implanted with its Iluvien diabetic macular edema (DME) treatment.
China's first free trade zone tipped to open access to investors
16 January, 2014China's piloting of its first free trade zone (FTZ) in Shanghai is drawing interest from Australian business, following its launch in late 2013. Backed by Chinese Premier Li Keqiang, the FTZ is expected to be a testing ground for a number of economic reforms, with its tax-free period of 10 years for businesses and the permitting of yuan convertibility and unrestricted foreign currency exchange in the area.
ResMed launches improved nasal pillow
16 January, 2014 by Dylan Bushell-EmblingResMed (ASX:RMD) said the improvements made to its latest AirFit nasal pillows improve sleeping time and compliance in sleep-disordered breathing patients.
Aussie biotechs had an "outstanding" 2013
14 January, 2014 by Dylan Bushell-EmblingThe Australian listed biotech sector handily outperformed both the All Ordinaries and the Health Care Index last year, analysis from Bioscience Managers shows.
Ease into the new year with resolutions to grow the biotech industry
14 January, 2014The new year has dawned with news that biotechnology has become a "20-year overnight success", with The Age and The Sydney Morning Herald (4/1/14) reporting that "biotech has finally boomed". The article reported the array of successes of 2013, which included IPOs, four- to nine-fold surges in share prices for a number of companies, high-profile investors turning their attention to biotech and a steady flow of capital raisings that totalled $739.1 million (Biotech Daily, 2/1/14), the highest amount since 2007.
Analytica names new director
13 January, 2014 by Dylan Bushell-EmblingSeasoned biotechnology executive Carl Stubbings has today commenced his tenure as non-executive director of medical device company Analytica (ASX:ALT).
NSW launches second-round Medical Devices Fund
08 January, 2014 by Dylan Bushell-EmblingThe NSW Ministry of Health will soon start taking applications for the second round of a $5m per year grant program for medical device companies.
UQ boffins shrink C3a into a small molecule
12 December, 2013 by Dylan Bushell-EmblingUniversity of Queensland scientists have discovered a way of converting large proteins into small molecules suitable for drug development, while retaining their key properties.
AusBiotech wraps up a year of delivery for the industry
12 December, 2013As we head into Christmas and the New Year, the industry's ASX-listed market capitalisation sits just over $50 billion and there are signs that the IPO market is at last awakening from hibernation. The year has proven to be another solid period for the Australian biotechnology industry and for AusBiotech. During this time, AusBiotech was steadfast in its advocacy and active in its representation and support of the industry.
Avita CEO steps down after first strike
11 December, 2013 by Dylan Bushell-EmblingAvita Medical (ASX:AVH) has appointed interim replacements for its CEO and chairman and has started reviewing its remuneration policy following last month's 'first strike' vote.
Pharmaxis' Bronchitol to get Scottish NHS listing
11 December, 2013 by Dylan Bushell-EmblingThe Scottish Medicines Consortium (SMC) has accepted Bronchitol for use by the nation's National Health Service as an adjunct therapy in adult cystic fibrosis patients.
Industry welcomes resurgence of IPOs
10 December, 2013With the initial public offering (IPO) of medical device distributor LifeHealthcare Group last week and the IPO launch of New Zealand-based Innate Immunotherapeutics the week prior, expectations are growing that we will see a reawakening of the biotechnology IPO market the coming year.
